Venus Remedies Ltd Stock Price Today (NSE: VENUSREM)
Fundamental Score
Venus Remedies Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Venus Remedies Ltd share price today is ₹1581.60, down 1.36% on NSE/BSE as of 31 July 2026. Venus Remedies Ltd (VENUSREM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.44K (Cr). The 52-week high for VENUSREM share price is ₹2044.30 and the 52-week low is ₹424.00. At a P/E ratio of 23.76x, VENUSREM is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 16.79% and a debt-to-equity ratio of 0.02.
Venus Remedies Ltd Share Price Chart — NSE/BSE Historical Performance
Venus Remedies Ltd share price chart: -9.72% return over the past month. 52-week high ₹2044.30, 52-week low ₹424.00.
Venus Remedies Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1539.00 | ₹1598.90 | ₹1525.00 | ₹1581.60 | 24.52K (Cr) | |
| ₹1528.00 | ₹1607.20 | ₹1471.10 | ₹1603.40 | 35.89K (Cr) | |
| ₹1530.10 | ₹1610.00 | ₹1493.40 | ₹1530.70 | 98.37K (Cr) | |
| ₹1649.00 | ₹1699.00 | ₹1566.60 | ₹1572.00 | 70.00K (Cr) | |
| ₹1621.10 | ₹1778.50 | ₹1615.00 | ₹1775.50 | 96.95K (Cr) | |
| ₹1740.30 | ₹1770.00 | ₹1681.50 | ₹1693.90 | 67.33K (Cr) | |
| ₹1755.00 | ₹1820.00 | ₹1705.10 | ₹1770.00 | 30.93K (Cr) | |
| ₹1844.10 | ₹1849.00 | ₹1775.00 | ₹1788.50 | 19.97K (Cr) | |
| ₹1959.00 | ₹1959.00 | ₹1821.60 | ₹1843.80 | 44.24K (Cr) | |
| ₹1818.00 | ₹1895.60 | ₹1818.00 | ₹1895.60 | 65.31K (Cr) |
Venus Remedies Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1741.90 | ₹1959.00 | ₹1471.10 | ₹1581.60 | -9.20% | |
| ₹1344.10 | ₹2044.30 | ₹1344.10 | ₹1833.50 | +36.41% | |
| ₹998.90 | ₹1280.05 | ₹880.05 | ₹1280.05 | +28.15% | |
| ₹859.00 | ₹1088.80 | ₹831.10 | ₹967.40 | +12.62% | |
| ₹646.00 | ₹944.75 | ₹622.10 | ₹820.05 | +26.94% | |
| ₹831.45 | ₹837.45 | ₹664.00 | ₹672.40 | -19.13% | |
| ₹780.00 | ₹820.55 | ₹685.00 | ₹818.55 | +4.94% | |
| ₹695.30 | ₹839.90 | ₹665.30 | ₹766.10 | +10.18% | |
| ₹434.35 | ₹758.00 | ₹433.70 | ₹691.15 | +59.12% | |
| ₹445.05 | ₹488.10 | ₹432.10 | ₹434.35 | -2.40% | |
| ₹436.00 | ₹482.65 | ₹424.00 | ₹440.05 | +0.93% | |
| ₹530.00 | ₹542.70 | ₹448.00 | ₹455.95 | -13.97% |
AI Research Briefing
Powered by Gemini · 2026-04-13
Micro-cap pharma play riding momentum and government tailwinds, but liquidity risk is a thesis killer.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Venus Remedies delivered a strong weekly performance from April 6 to April 10, rising 7.66% from to , outperforming the Sensex's 5.34% gain. The stock hit a fresh 52-week high of on April 10. The company has also announced a special window for re-lodgement of physical share transfer requests.
CORE STORY (THE REAL GAME)
Venus Remedies is being priced as a high-growth, small-cap pharma play, riding the wave of increased domestic manufacturing and innovation in the Indian pharmaceutical sector. The market is betting on its ability to scale up and capitalize on government incentives and global collaborations.
- Strong quarterly results with 30.51% YoY net profit growth
- Stock hitting new 52-week highs, indicating bullish momentum
- Government support through PLI scheme
- New order wins and contract manufacturing agreements
- Successful expansion into new markets
- Positive developments in research and development
- Micro-cap liquidity risk
- Dependence on government incentives and regulatory approvals
- Promoter group merger adds complexity
FII down 0.39%, DII up 0.64% — mixed signals, no clear conviction.
Government push for domestic pharma manufacturing is a tailwind, but global supply chain issues remain a concern.
Free Cash Flow 5Y: ₹294.63 Cr — Profit converting to cash, but needs closer monitoring.
Expect continued volatility. Focus on execution and order book. Next 3-6 months will determine if this rally is sustainable.
Primary Thesis Risk
Liquidity dries up, and the music stops.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Venus Remedies Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Venus Remedies Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VENUSREM across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (16.79%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.67%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 23.76 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (126.19%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (33.05%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (19.88% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (21.81% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (3355.00x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹281.04 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Limited Institutional Interest (FII+DII: 4.00%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Venus Remedies Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Venus Remedies Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Venus Remedies LtdVenus Remedies ...Selected✓ VENUSREM • 526953 | 75.2/100 | ₹1581.60₹1582 | ₹2442.32₹2442.32 | 23.76Average 23.8 Average | 16.79%Good 16.79% Good | 21.67%Excellent 21.67% Excellent | 0.02Excellent 0.0 Excellent | 21.81%Excellent 21.81% Excellent | 7.18%Good 7.18% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Venus Remedies Ltd PE Ratio History
Historical price-to-earnings ratio for VENUSREM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹33.90 | ₹766.10 | 22.6x |
| FY 2024 | ₹21.31 | ₹318.45 | 14.9x |
| FY 2023 | ₹19.88 | ₹406.25 | 20.4x |
| FY 2022 | ₹30.86 | ₹127.85 | 4.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Venus Remedies Ltd Quarterly Performance
Latest quarterly metrics for VENUSREM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
33.05%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
126.19%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
7.18%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
21.81%
Compounded annual net profit growth over 5 years
Venus Remedies Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VENUSREM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Venus Remedies Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Venus Remedies Ltd (VENUSREM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Venus Remedies Ltd
About VENUSREM (Venus Remedies Ltd)
Venus Remedies Ltd is a pioneering force in the global pharmaceutical landscape, committed to innovation and excellence in addressing critical healthcare challenges. With a steadfa...st dedication to research and development, the company focuses on developing cutting-edge solutions, particularly in the fields of antimicrobial resistance and oncology. Venus Remedies operates on a global scale, distributing its products and forging strategic partnerships to ensure accessibility to its life-saving treatments. The company's commitment to quality and patient well-being is evident in its state-of-the-art manufacturing facilities and adherence to stringent regulatory standards, positioning it as a trusted and reliable provider of pharmaceutical solutions worldwide. The company boasts a comprehensive portfolio of pharmaceutical products, catering to a wide spectrum of therapeutic areas. Venus Remedies offers a range of medications including pain relievers, antibiotics, and treatments for cardiovascular diseases. Furthermore, their product line includes gastrointestinal therapies, liver protection agents, and hormone-based treatments. Recognizing the significance of supportive care, the company also provides immunostimulating agents, iron supplements, and muscle relaxants. Venus Remedies maintains a commitment to advancing patient care by continually developing and refining its pharmaceutical offerings, ensuring that healthcare professionals have access to the tools they need to provide optimal treatment outcomes. Driven by a vision to improve global health, Venus Remedies prioritizes research and development to tackle pressing medical needs. The company's investment in innovative therapies, particularly in combating antimicrobial resistance and developing novel cancer treatments, reflects its commitment to addressing some of the most significant challenges facing the healthcare industry. By fostering a culture of scientific excellence and collaboration, Venus Remedies strives to develop groundbreaking solutions that enhance patient outcomes and improve the quality of life for individuals around the world. Their dedication to innovation and global health positions them as a leader in the pharmaceutical sector.
Company Details
Key Leadership
Corporate Events
VENUSREM Share Price: Frequently Asked Questions
What is the current share price of Venus Remedies Ltd?
Venus Remedies Ltd (VENUSREM) trades at ₹1581.60 on NSE and BSE. Market cap ₹2.44K (Cr). Educational data only.
What is the P/E ratio of Venus Remedies Ltd?
Venus Remedies Ltd has a P/E of 23.76x vs industry average 34.89x.
What is the Bull Run score for Venus Remedies Ltd?
Venus Remedies Ltd has a Bull Run score of 75.2/100 based on 25+ financial parameters.
Does Venus Remedies Ltd pay dividends?
Venus Remedies Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Venus Remedies Ltd?
Venus Remedies Ltd has ROE of 16.79%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Venus Remedies Ltd?
Venus Remedies Ltd has debt-to-equity of 0.02.
Is Venus Remedies Ltd a good investment?
Bull Run gives Venus Remedies Ltd a score of 75.2/100. This is not investment advice — consult a SEBI-registered advisor.